参与产科研究与非参与者的妊娠结局比较
该回顾性队列研究纳入2013至2018年单中心分娩的19569例患者,比较参与产科研究(3848例)与未参与(15721例)者的母儿结局。参与者复合母体病率(9.2% vs 8.7%,调整OR 0.83,95%CI 0.73-0.95)和复合新生儿病率(27.5% vs 18.6%,调整OR 0.53,95%CI 0.48-0.58)均显著降低。
要点
- 参与产科研究者复合母体病率9.2% vs 未参与者8.7%,调整OR 0.83(95%CI 0.73-0.95)。
- 参与研究者复合新生儿病率27.5% vs 未参与者18.6%,调整OR 0.53(95%CI 0.48-0.58)。
- 母体病率降低仅见于试验参与者,新生儿病率降低见于试验和观察性研究参与者。
核心结论
- 调整潜在混杂因素后,参与产科研究与母体和新生儿病率降低相关。
- 作者认为这凸显了孕妇参与产科临床研究并可能从额外监测中获益的重要性。
- 作者指出需要进一步研究研究参与如何影响妊娠结局。
研究设计与样本
- 回顾性队列研究,纳入2013至2018年单中心所有分娩患者,排除孕13周前妊娠丢失或重大胎儿畸形者。
- 共纳入19569例患者,其中研究参与者3848例(19.7%),非参与者15721例(80.3%)。
- 参与者中3023例(78.6%)参与试验,825例(21.4%)参与观察性研究。
- 主要结局为分娩后6周内诊断的复合母体病率,次要结局包括复合新生儿病率及其他围产结局。
- 采用双变量分析比较基线人口学和结局,多变量逻辑回归估计调整比值比及95%置信区间,并按研究设计(试验或观察性)进行亚组分析。
主要发现
- 研究参与者较非参与者体重指数更高,更年轻、非西班牙裔黑人、公共保险、初产和剖宫产的比例更高。
- 参与者复合母体病率9.2% vs 非参与者8.7%,调整OR 0.83(95%CI 0.73-0.95)。
- 参与者复合新生儿病率27.5% vs 非参与者18.6%,调整OR 0.53(95%CI 0.48-0.58)。
- 参与者胎儿死亡、5分钟Apgar评分<5、新生儿死亡、母体和新生儿重症监护病房入住及住院时间的 odds 均低于非参与者。
- 分层分析中,母体病率仅在试验参与者中显著降低;无论研究设计(试验或观察性 vs 未参与研究),新生儿病率 odds 均显著降低。
关键数值与推荐
- 复合母体病率:参与者9.2% vs 非参与者8.7%,调整OR 0.83(95%CI 0.73-0.95)。
- 复合新生儿病率:参与者27.5% vs 非参与者18.6%,调整OR 0.53(95%CI 0.48-0.58)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为孕妇参与产科临床研究可能从额外监测中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between pregnant patients participating in obstetrical studies and pregnancy outcomes is understudied. OBJECTIVE: This study aimed to evaluate the association between participation in obstetrical studies and maternal and neonatal outcomes. STUDY DESIGN: This was a retrospective cohort study of all patients delivering at a single center from 2013 to 2018. Patients with pregnancy loss at <13 weeks of gestation or major fetal anomalies were excluded. Patients who enrolled in one or more obstetrical studies were categorized as "study participants" and were compared with patients who did not enroll in an obstetrical study, that is, "study nonparticipants." The primary outcome was a composite of maternal morbidity diagnosed up to 6 weeks after delivery. The secondary outcomes included composite neonatal morbidity and other perinatal outcomes. Bivariate analyses compared baseline demographics and outcomes between groups. Multivariable logistic regression was used to estimate adjusted odds ratios with 95% confidence intervals. Subgroup analyses by study design (trial or observational) were planned. RESULTS: Of 19,569 patients included in this analysis, 3848 (19.7%) were study participants, and 15,721 (80.3%) were study nonparticipants. Among study participants, 3023 (78.6%) enrolled in a trial, and 825 (21.4%) enrolled in an observational study. The study participants had higher body mass index and were more likely to be younger, non-Hispanic Black, publicly insured, nulliparous, and undergo cesarean delivery than study nonparticipants. Compared with study nonparticipants, the study participants had significantly lower odds of composite maternal morbidity (9.2% vs 8.7%; adjusted odds ratio, 0.83; 95% confidence interval, 0.73-0.95) and composite neonatal morbidity (27.5% vs 18.6%; adjusted odds ratio, 0.53; 95% confidence interval, 0.48-0.58). In addition, the odds of fetal death, 5-minute Apgar score of <5, neonatal death, maternal and neonatal intensive care unit admissions, and lengths of stay were lower for study participants than for study nonparticipants. In stratified analyses, maternal morbidity was only significantly decreased among trial participants; however, there was a significantly reduced odds of neonatal morbidity, regardless of study design (trial or observational vs no study). CONCLUSION: Participation in obstetrical studies was associated with decreased maternal and neonatal morbidities after adjusting for potential confounders. This underscored the importance of pregnant patients enrolling in obstetrical clinical studies and potentially benefiting from the additional surveillance. Further study of how study participation exerts this effect on pregnancy outcomes is warranted.
引用
- Cozzi GD, Jauk VC, Szychowski JM, et al. Participation in obstetrical studies is associated with improved pregnancy outcomes. Am J Obstet Gynecol MFM. 2022. PMID: 35995368. doi:10.1016/j.ajogmf.2022.100729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。